20131203_6

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
ISSUE 42 – NOV. 8, 2013PDF

example

Wicha to Leave Director’s Job at UMich

Conversation with The Cancer Letter: Max Wicha

After 27 years and six NCI cancer center support grants, Max Wicha announced he would step down as director of the University of Michigan Comprehensive Cancer Center.

“Frankly, my research is really going well now,” Wicha said in a Q&A with The Cancer Letter. “It’s in a very exciting phase in researching cancer stem cells. My lab has grown—and my work is now moving into the clinic, so I’m actually working with our clinical people to do clinical trials targeting cancer stem cells.

“So the idea of five more years, or do I get to really focus on my research now? That was really the deciding factor.

“So it’s time. Again, six core grants is quite a number.”

photoBioMarin CEO Fires Off Feisty Emails In Battle Over Access to PARP Inhibitor

More than 230,000 people—including 82 Texas state lawmakers—petitioned BioMarin Pharmaceutical Inc. to provide its investigational drug to an Austin attorney afflicted with stage IIIC ovarian cancer.

photoIn Brief
  • Lynne Penberthy named NCI DCCPS associate director for surveillance

  • Michele Bloch appointed chief of NCI Tobacco Control Research Branch

  • MD Anderson’s James Allison named 2013 Innovations Award winner in Bioscience by The Economist

  • European Commission approves Yervoy for first-line treatment of adult unresectable or metastatic melanoma

  • FDA approves generic Morphine Sulfate Injection

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login